Search | Clinical Trials Finder

Conditions: Ovarian Cancer
Interventions: Glufosfamide; Drug
Lead sponsor: Eleison Pharmaceuticals LLC.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 7 more

Conditions: Ovarian Diseases, Ovarian Neoplasms
Interventions: Laboratory Tumor Marker Analysis, Transvaginal Ultrasound, Health Status Questionnaire; Other
Lead sponsor: Swedish Medical Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Platinum Sensitive Relapsed Ovarian Cancer
Interventions: OLAPARIB, PLACEBO; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more

Conditions: Ovarian Cancer
Interventions: Early detection; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years and older · Female only
Enrollment: 2,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Stage IV, Ovarian Cancer Recurrent, Ovarian Cancer Stage III, Ovary Cancer
Interventions: Oregovomab, Poly ICLC; Biological · Drug
Lead sponsor: CanariaBio Inc.; Industry
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Richmond, Virginia

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions: 27T51, Cemiplimab, Bevacizumab; Other · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more

Conditions: Ovarian Cancer
Interventions: Olaparib; Drug
Lead sponsor: Sarah E Taylor; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Neoplasm, Primary Peritoneal Carcinoma
Interventions: Evaluation of Cancer Risk Factors, Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 1,916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 141
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more

Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions: 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery; Procedure · Drug · Other + 2 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Interventions: Ubamatamab, Marlotamig, Sarilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 15
States / cities: Goodyear, Arizona • Irvine, California • Washington D.C., District of Columbia + 11 more

Conditions: PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Interventions: HWK-016, MUCIN-16-targeted ADC, Bevacizumab; Drug
Lead sponsor: Whitehawk Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Sarasota, Florida + 9 more

Conditions: Ovarian Cancer, Genitourinary (GU) Tumors
Interventions: Epacadostat, tamoxifen; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Culdocentesis, Vaginal Swab, Chromopertubation, Blood collection, Tissue collection; Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer
Interventions: Lenvatinib, Carboplatin, Gemcitabine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions: Vaginal Fluid Collection, Blood Collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 20 more

Conditions: Ovarian Neoplasms
Interventions: Carboplatin, Paclitaxel, oregovomab; Drug · Biological
Lead sponsor: Quest PharmaTech Inc.; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Farmington, Connecticut • South Bend, Indiana

Conditions: Ovarian Cancer, Primary Peritoneal Carcinoma
Interventions: Å6 subcutaneous injection; Drug
Lead sponsor: Ångstrom Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 24
States / cities: Birmingham, Alabama • Casa Grande, Arizona • Fresno, California + 21 more

Conditions: Ovarian Cancer
Interventions: Not listed
Lead sponsor: Southern Illinois University; Other
Eligibility: 30 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Autologous Monocytes + ACTIMMUNE + SYLATRON; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epithelial Ovarian Cancer
Interventions: Farletuzumab, Carboplatin, and PLD; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Brightwaters, New York + 2 more

Conditions: Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Mixed Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Ovarian Neoplasm, Malignant Ovarian Serous Tumor, Malignant Ovarian Transitional Cell Tumor, Ovarian Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 131
States / cities: Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 99 more

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years to 100 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: oregovomab; Biological
Lead sponsor: AltaRex; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 15
States / cities: Newport Beach, California • Fort Myers, Florida • Orlando, Florida + 11 more

Conditions: Ovarian Carcinoma, Ovarian Germ Cell Tumor
Interventions: Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging; Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 74 Years · Female only
Enrollment: 78,216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels

Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)